Berlin - Delayed Quote EUR

bluebird bio Inc (BLE.BE)

Compare
0.3708 -0.0115 (-3.01%)
As of December 12 at 9:40:04 PM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BLE.BE

Recent News: BLE.BE

View More
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire last month
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire last month
bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Announces 1-for-20 Reverse Stock Split
Business Wire last month
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Business Wire last month
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
Benzinga last month
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. last month
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Benzinga last month
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
GuruFocus.com last month
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Zacks last month

Bluebird: Q3 Earnings Snapshot
Associated Press Finance last month
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
Business Wire last month
View More

Related Tickers

7IZ.MU Ziccum AB
0.0298
-29.72%
 
IKAP.MU Aurinia Pharmaceuticals Inc
8.14
0.00%
 
5KW.F SkinBioTherapeutics plc
0.1660
-2.35%
 
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%
 
XRP2.F Silence Therapeutics plc
5.95
+0.85%
 
ORN.F Oryzon Genomics S.A.
1.5020
+2.18%
 
ALGEN.PA genOway Société anonyme
3.9000
+1.04%
 
41X.F Ardelyx, Inc.
5.12
+0.16%
 
PH4.F CStone Pharmaceuticals
0.2640
-1.49%
 
BV3.DU Bavarian Nordic A/S
27.15
+0.56%